2种给药方式的胂酸基乙酸对H_(22)肝癌荷瘤小鼠的抑瘤作用比较

目的 :比较不同给药方式的胂酸基乙酸 (ASAC)对H22 肝癌移植瘤在小鼠体内生长的抑制作用。方法 :采用腹腔注射和静脉注射2种给药方式 ,分别在小鼠右腋皮下接种肝癌H22 细胞后 ,随机将其分为5组 ,分别注射生理盐水、环磷酰胺及不同剂量的ASAC ,观察癌细胞株的成瘤率、受试物对H22 肝癌荷瘤小鼠的抑瘤作用及其对小鼠脏器的影响。结果 :与腹腔注射给药方式比较 ,静脉注射给予ASAC高、中、低剂量后均产生显著抑制肿瘤生长作用 ,其抑瘤率分别为46. 59 %、46 .31 %和32 .48 % ;2种给药方式的ASAC低剂量组小鼠脾重指数均有升高 ,但静脉注射给予ASAC高剂量组出现了小鼠中毒死亡。结论 :与腹腔注射给药方式比较 ,ASAC静脉注射给药方式的抑瘤作用更好。     

l-Carnitine–supplemented parenteral nutrition improves fat metabolism but fails to support compensatory growth in premature Korean infants

We have previously shown that pregnant Korean mothers often have especially poor carnitine status, which may be responsible for the suboptimal carnitine levels of newborn Korean infants. This study tested the hypothesis that carnitine obtained from premature infant formula alone is adequate in sustaining optimal lipid metabolism and growth in premature infants. Accordingly, we investigated the effects of parenteral carnitine supplementation on carnitine status, growth parameters, and lipid metabolism in premature infants by measuring serum lipid profiles, carnitine and β-hydroxybutyrate concentrations, and body weight, size, and length. Twenty-five low–birth weight Korean infants were randomly assigned to control (LCNS, n = 12) or l-carnitine–supplemented (10 mg/[kg d], LCS, n = 13) groups. On day 9, the triacylglycerol concentration was lower in the LCS group; but the high-density lipoprotein cholesterol concentration and free, acyl, and total carnitine and β-hydroxybutyrate were significantly increased compared with the LCNS group. The ratio of acyl carnitine to free carnitine was significantly lower on day 5 in the LCS compared with the LCNS group. Body weight, height, Apgar score (1 and 5 minute), head circumference, and chest circumference were recorded on day 0; and body weight was measured again on days 5 and 9. Infant formula intake was recorded every day. There was no significant difference in body weight or growth parameters between the groups from days 0 to 9.Therefore, we concluded that, in low–birth weight infants, the addition of 10 mg/(kg d) supplemental carnitine significantly improves lipid profiles and serum carnitine level but does not enhance growth.